News

The stock is known to soar on good news.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Novo Nordisk stock has delivered a decline of 32.7% over the past three years, yet current valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks, both point to the shares trading at a discount to what the business may be worth. The three-year return of 32.7% down raises the question of whether sentiment has moved further than the underlying value of Novo Nordisk. Medicare’s decision to cover certain GLP-1 weight loss drugs and growing use...

The new unit will start with $2.5 billion to help companies choose and use AI tools.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock’s inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next 12-months making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) one of the Best Rising Penny Stocks to Buy According […]

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Market research highlights Novo Nordisk (NYSE:NVO) as a leading company in the global antidiabetic drugs market. The report points to rising diabetes prevalence and new therapeutic approaches as key drivers for the sector. Novo Nordisk is identified as a major participant in advanced drug classes, including GLP-1 receptor agonists. Novo Nordisk is a central player in a global antidiabetic market that research identifies as having significant long-term potential, with diabetes prevalence and...

Novo Nordisk stock has given investors a mixed ride over the past few years, with a 36.1% gain over 5 years but weaker recent returns, and the valuation checks now suggest the shares may lean cheap rather than fully priced in. Over the last 5 years, Novo Nordisk has returned 36.1%, which points to a longer term story that still created value even though shorter term performance has been more muted. Recent headlines around Medicare’s GLP-1 Bridge program and expanding cardiometabolic research...

The new company will focus on integrating enterprise AI, offering tailored support and protecting client data and intellectual property.

Microsoft shares soar as the behemoth announces a $2.5 billion investment in a new initiative, Microsoft Frontier Co. But does that warrant buying MSFT stock today?

Microsoft (MSFT) is launching a new business unit with a $2.5 billion investment that will help clie

European stock markets closed higher Thursday, paced by defense and luxury goods, while oil prices f

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.

Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ temporary Bridge program, a federal initiative designed to expand GLP-1 obesity drug coverage for eligible seniors at a $50 monthly copay. The...

In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

European equities traded in the US as American depositary receipts were tracking sharply lower late

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

With an annual dividend yield of 3.75%, Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best NYSE Stocks to Buy for Dividends. Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark. On June 19, Nordea upgraded Novo Nordisk A/S (NYSE:NVO) from ‘Hold’ to ‘Buy’ and assigned the […]

Novo Nordisk has entered into an outsourcing agreement with Shantha Biologics for cartridge fill-finish manufacturing services in India. The partnership expands Novo Nordisk’s production footprint into a key pharmaceutical manufacturing hub. The deal is intended to support the company’s global supply chain and its ability to meet demand for cartridge-based products. Novo Nordisk, traded as CPSE:NOVO B, is making this move while its share price stands at DKK314.6. The stock is up 2.2% over...

Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.